Evaluating Tau Oligomers Passive Immunotherapy using Aged Transgenic Animals of Tauopathy

Rabab Al Lahham, Alice Bittar, Mariana Carretero Murillo, Salome McAllen, Nemil Bhatt, Anna Ellsworth, Rakez Kayed

Research output: Contribution to conferencePoster

Abstract

An estimated 5.5 million Americans have Alzheimer’s disease (AD), the most common type of dementia. With the incidence of AD and related dementias growing, due to the increase in life span, it is critical to develop approaches for early diagnosis and therapeutics to halt the progress of the disease. AD has been characterized by the accumulation of amyloid plaques as well as fibrillar tangles of hyperphosphorylated tau proteins. We and others have shown that Tau oligomers (TauO) are the toxic species responsible for the pathology of the disease. Passive immunotherapy targeting different tau species, which reduces the risks of immunological side effects and provides the flexibility needed to adjust the treatment for patients, is the most promising approach and have shown to be efficacious in many animals regardless of the target.
The goal of this project is to investigate the potential of passive immunotherapy with different clones of Tau oligomer monoclonal antibodies (TOMAs), in two different but complementary mouse models; hTau, which overexpresses WT human Tau, and JNPL3 overexpressing the P301L mutant. These animals were aged to 20-24 months for hTau, and 14-16 months for JNPL3 mice. Previous studies, including ours, used middle aged mice (3-8 months), therefore it is critical to evaluate TauO passive immunotherapy in aged mice since the disease pathology changes with age. We injected mice with 120 µg of different TOMA clones as well as non-specific IgG intravenously, and we assessed the cognitive functions of mice one-week post-injection using Y-maze and novel object recognition (NOR) tests, as well as the motor activity using Rotarod test. Brain tissues were analyzed by standard biochemical and immunohistochemical assays.
We found that certain TOMA clones reverse the tauopathy-related memory deficit of JNPL3 mice, in addition to improving motor function of hTau mice. This rescuing of the cognitive and motor phenotypes was parallel to a reduction in TauO levels, using western blot and slot blot analysis.
This is the first study testing tau passive immunotherapy in elderly animals and support our previous reports of oligomeric tau role in disease progression and validate the potential for TOMAs in reversing disease course. Currently, we are humanizing these TOMA clones for potential clinical trials for AD and related tauopathies
Original languageEnglish (US)
StateUnpublished - Dec 2017
Event2018 Neuroscience, Cell Biology, and Anatomy Departmental Retreat - Hotel Galvez, Galveston, United States
Duration: Dec 14 2017 → …

Conference

Conference2018 Neuroscience, Cell Biology, and Anatomy Departmental Retreat
CountryUnited States
CityGalveston
Period12/14/17 → …

Fingerprint

Tauopathies
Genetically Modified Animals
Passive Immunization
Monoclonal Antibodies
Alzheimer Disease
Clone Cells
Dementia
Rotarod Performance Test
Pathology
tau Proteins
Poisons
Amyloid Plaques
Memory Disorders
Cognition
Disease Progression
Early Diagnosis
Motor Activity
Immunoglobulin G
Western Blotting
Clinical Trials

Cite this

Al Lahham, R., Bittar, A., Carretero Murillo, M., McAllen, S., Bhatt, N., Ellsworth, A., & Kayed, R. (2017). Evaluating Tau Oligomers Passive Immunotherapy using Aged Transgenic Animals of Tauopathy. Poster session presented at 2018 Neuroscience, Cell Biology, and Anatomy Departmental Retreat, Galveston, United States.

Evaluating Tau Oligomers Passive Immunotherapy using Aged Transgenic Animals of Tauopathy. / Al Lahham, Rabab; Bittar, Alice; Carretero Murillo, Mariana; McAllen, Salome; Bhatt, Nemil; Ellsworth, Anna; Kayed, Rakez.

2017. Poster session presented at 2018 Neuroscience, Cell Biology, and Anatomy Departmental Retreat, Galveston, United States.

Research output: Contribution to conferencePoster

Al Lahham, R, Bittar, A, Carretero Murillo, M, McAllen, S, Bhatt, N, Ellsworth, A & Kayed, R 2017, 'Evaluating Tau Oligomers Passive Immunotherapy using Aged Transgenic Animals of Tauopathy' 2018 Neuroscience, Cell Biology, and Anatomy Departmental Retreat, Galveston, United States, 12/14/17, .
Al Lahham R, Bittar A, Carretero Murillo M, McAllen S, Bhatt N, Ellsworth A et al. Evaluating Tau Oligomers Passive Immunotherapy using Aged Transgenic Animals of Tauopathy. 2017. Poster session presented at 2018 Neuroscience, Cell Biology, and Anatomy Departmental Retreat, Galveston, United States.
Al Lahham, Rabab ; Bittar, Alice ; Carretero Murillo, Mariana ; McAllen, Salome ; Bhatt, Nemil ; Ellsworth, Anna ; Kayed, Rakez. / Evaluating Tau Oligomers Passive Immunotherapy using Aged Transgenic Animals of Tauopathy. Poster session presented at 2018 Neuroscience, Cell Biology, and Anatomy Departmental Retreat, Galveston, United States.
@conference{bb63179a54e74e8ab7baf6d76b5b6c61,
title = "Evaluating Tau Oligomers Passive Immunotherapy using Aged Transgenic Animals of Tauopathy",
abstract = "An estimated 5.5 million Americans have Alzheimer’s disease (AD), the most common type of dementia. With the incidence of AD and related dementias growing, due to the increase in life span, it is critical to develop approaches for early diagnosis and therapeutics to halt the progress of the disease. AD has been characterized by the accumulation of amyloid plaques as well as fibrillar tangles of hyperphosphorylated tau proteins. We and others have shown that Tau oligomers (TauO) are the toxic species responsible for the pathology of the disease. Passive immunotherapy targeting different tau species, which reduces the risks of immunological side effects and provides the flexibility needed to adjust the treatment for patients, is the most promising approach and have shown to be efficacious in many animals regardless of the target.The goal of this project is to investigate the potential of passive immunotherapy with different clones of Tau oligomer monoclonal antibodies (TOMAs), in two different but complementary mouse models; hTau, which overexpresses WT human Tau, and JNPL3 overexpressing the P301L mutant. These animals were aged to 20-24 months for hTau, and 14-16 months for JNPL3 mice. Previous studies, including ours, used middle aged mice (3-8 months), therefore it is critical to evaluate TauO passive immunotherapy in aged mice since the disease pathology changes with age. We injected mice with 120 µg of different TOMA clones as well as non-specific IgG intravenously, and we assessed the cognitive functions of mice one-week post-injection using Y-maze and novel object recognition (NOR) tests, as well as the motor activity using Rotarod test. Brain tissues were analyzed by standard biochemical and immunohistochemical assays.We found that certain TOMA clones reverse the tauopathy-related memory deficit of JNPL3 mice, in addition to improving motor function of hTau mice. This rescuing of the cognitive and motor phenotypes was parallel to a reduction in TauO levels, using western blot and slot blot analysis. This is the first study testing tau passive immunotherapy in elderly animals and support our previous reports of oligomeric tau role in disease progression and validate the potential for TOMAs in reversing disease course. Currently, we are humanizing these TOMA clones for potential clinical trials for AD and related tauopathies",
author = "{Al Lahham}, Rabab and Alice Bittar and {Carretero Murillo}, Mariana and Salome McAllen and Nemil Bhatt and Anna Ellsworth and Rakez Kayed",
year = "2017",
month = "12",
language = "English (US)",
note = "2018 Neuroscience, Cell Biology, and Anatomy Departmental Retreat ; Conference date: 14-12-2017",

}

TY - CONF

T1 - Evaluating Tau Oligomers Passive Immunotherapy using Aged Transgenic Animals of Tauopathy

AU - Al Lahham, Rabab

AU - Bittar, Alice

AU - Carretero Murillo, Mariana

AU - McAllen, Salome

AU - Bhatt, Nemil

AU - Ellsworth, Anna

AU - Kayed, Rakez

PY - 2017/12

Y1 - 2017/12

N2 - An estimated 5.5 million Americans have Alzheimer’s disease (AD), the most common type of dementia. With the incidence of AD and related dementias growing, due to the increase in life span, it is critical to develop approaches for early diagnosis and therapeutics to halt the progress of the disease. AD has been characterized by the accumulation of amyloid plaques as well as fibrillar tangles of hyperphosphorylated tau proteins. We and others have shown that Tau oligomers (TauO) are the toxic species responsible for the pathology of the disease. Passive immunotherapy targeting different tau species, which reduces the risks of immunological side effects and provides the flexibility needed to adjust the treatment for patients, is the most promising approach and have shown to be efficacious in many animals regardless of the target.The goal of this project is to investigate the potential of passive immunotherapy with different clones of Tau oligomer monoclonal antibodies (TOMAs), in two different but complementary mouse models; hTau, which overexpresses WT human Tau, and JNPL3 overexpressing the P301L mutant. These animals were aged to 20-24 months for hTau, and 14-16 months for JNPL3 mice. Previous studies, including ours, used middle aged mice (3-8 months), therefore it is critical to evaluate TauO passive immunotherapy in aged mice since the disease pathology changes with age. We injected mice with 120 µg of different TOMA clones as well as non-specific IgG intravenously, and we assessed the cognitive functions of mice one-week post-injection using Y-maze and novel object recognition (NOR) tests, as well as the motor activity using Rotarod test. Brain tissues were analyzed by standard biochemical and immunohistochemical assays.We found that certain TOMA clones reverse the tauopathy-related memory deficit of JNPL3 mice, in addition to improving motor function of hTau mice. This rescuing of the cognitive and motor phenotypes was parallel to a reduction in TauO levels, using western blot and slot blot analysis. This is the first study testing tau passive immunotherapy in elderly animals and support our previous reports of oligomeric tau role in disease progression and validate the potential for TOMAs in reversing disease course. Currently, we are humanizing these TOMA clones for potential clinical trials for AD and related tauopathies

AB - An estimated 5.5 million Americans have Alzheimer’s disease (AD), the most common type of dementia. With the incidence of AD and related dementias growing, due to the increase in life span, it is critical to develop approaches for early diagnosis and therapeutics to halt the progress of the disease. AD has been characterized by the accumulation of amyloid plaques as well as fibrillar tangles of hyperphosphorylated tau proteins. We and others have shown that Tau oligomers (TauO) are the toxic species responsible for the pathology of the disease. Passive immunotherapy targeting different tau species, which reduces the risks of immunological side effects and provides the flexibility needed to adjust the treatment for patients, is the most promising approach and have shown to be efficacious in many animals regardless of the target.The goal of this project is to investigate the potential of passive immunotherapy with different clones of Tau oligomer monoclonal antibodies (TOMAs), in two different but complementary mouse models; hTau, which overexpresses WT human Tau, and JNPL3 overexpressing the P301L mutant. These animals were aged to 20-24 months for hTau, and 14-16 months for JNPL3 mice. Previous studies, including ours, used middle aged mice (3-8 months), therefore it is critical to evaluate TauO passive immunotherapy in aged mice since the disease pathology changes with age. We injected mice with 120 µg of different TOMA clones as well as non-specific IgG intravenously, and we assessed the cognitive functions of mice one-week post-injection using Y-maze and novel object recognition (NOR) tests, as well as the motor activity using Rotarod test. Brain tissues were analyzed by standard biochemical and immunohistochemical assays.We found that certain TOMA clones reverse the tauopathy-related memory deficit of JNPL3 mice, in addition to improving motor function of hTau mice. This rescuing of the cognitive and motor phenotypes was parallel to a reduction in TauO levels, using western blot and slot blot analysis. This is the first study testing tau passive immunotherapy in elderly animals and support our previous reports of oligomeric tau role in disease progression and validate the potential for TOMAs in reversing disease course. Currently, we are humanizing these TOMA clones for potential clinical trials for AD and related tauopathies

M3 - Poster

ER -